Why the study?
Therapies that increase HDL-C levels have failed to achieve clinical benefit in patients with known ASCVD, despite epidemiologic studies demonstrating an inverse association between HDL-C and ASCVD.
Epidemiologic studies have previously demonstrated an inverse association between high-density lipoprotein cholesterol (HDL-C) levels and atherosclerotic cardiovascular disease (ASCVD) [1]. This has led to an expectation that therapeutically increasing HDL-C levels could yield clinically significant benefits. However, therapies, such as niacin and most cholesteryl ester transfer protein inhibitors, which increase HDL-C levels by approximately 20%–40%, have failed to achieve benefit in patients with known ASCVD [2,3].
No takes yet. Share an insight, caveat, or question.
Salagaras et al. (2026) studied Non-ST-Elevation Myocardial Infarction / Atherosclerotic Cardiovascular Disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: